Nurix Therapeutics (NRIX) Income from Continuing Operations (2019 - 2026)
Nurix Therapeutics (NRIX) posted quarterly Income from Continuing Operations of 89535000.0 for Q2 2026, down 106.0% year-over-year from 1492730817.03 in Q2 2025, and down 1.8% quarter-over-quarter from 87949000.0 in Q1 2026.
Powered by 
Analysis
Nurix Therapeutics (NRIX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has reported Income from Continuing Operations for 8 consecutive years, with 89535000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Income from Continuing Operations fell 106.0% year-over-year to 89535000.0; the TTM figure through May 2026 stood at 342126000.0 (down 65.02% YoY), while the FY2025 annual figure was 264457000.0, down 36.62% from the prior year.
- Income from Continuing Operations declined to 89535000.0 in Q2 2026 per NRIX's latest filing, from 87949000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 24277000.0 in Q2 2023 and bottomed at 89535000.0 in Q2 2026.
- Historically, Income from Continuing Operations has averaged 53323222.22 across 5 years, with a median of 45555000.0 in 2022.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations surged 46.53% — and 2026, when it tumbled 106.0%.
- Nurix Therapeutics' Income from Continuing Operations stood at 46717000.0 in 2022, then advanced by 10.19% to 41956000.0 in 2023, then sank by 39.55% to 58549000.0 in 2024, then tumbled by 33.6% to 78221000.0 in 2025, then declined by 14.46% to 89535000.0 in 2026.
- Business Quant data shows NRIX's Income from Continuing Operations at 89535000.0 in Q2 2026, 87949000.0 in Q1 2026, and 78221000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Nurix Therapeutics | 2.86 Bn | 2.42 Bn | - | -89.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | -89.54 Mn |
| Feb 28, 2026 | -87.17 Mn |
| Nov 30, 2025 | -78.22 Mn |
| Aug 31, 2025 | -86.42 Mn |
| May 31, 2025 | -43.46 Mn |
| Feb 28, 2025 | -56.35 Mn |
| Nov 30, 2024 | -58.55 Mn |
| Aug 31, 2024 | -48.96 Mn |
| May 31, 2024 | -44.55 Mn |
| Feb 29, 2024 | -41.52 Mn |
| Nov 30, 2023 | -41.96 Mn |
| Aug 31, 2023 | -36.98 Mn |
| May 31, 2023 | -24.28 Mn |
| Feb 28, 2023 | -40.73 Mn |
| Nov 30, 2022 | -46.72 Mn |
| Aug 31, 2022 | -45.71 Mn |
| May 31, 2022 | -45.40 Mn |
| Feb 28, 2022 | -42.53 Mn |
| Nov 30, 2021 | -37.69 Mn |
| Aug 31, 2021 | -28.84 Mn |